- Home
- OTRK vs KZIA Comparison
OTRK vs KZIA Comparison
Compare OTRK & KZIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OTRK
- KZIA
- Stock Information
- Founded
- OTRK 2003
- KZIA 1994
- Country
- OTRK United States
- KZIA Australia
- Employees
- OTRK N/A
- KZIA N/A
- Industry
- OTRK Misc Health and Biotechnology Services
- KZIA Biotechnology: Pharmaceutical Preparations
- Sector
- OTRK Health Care
- KZIA Health Care
- Exchange
- OTRK Nasdaq
- KZIA Nasdaq
- Market Cap
- OTRK 6.9M
- KZIA 7.8M
- IPO Year
- OTRK N/A
- KZIA 1999
- Fundamental
- Price
- OTRK $1.75
- KZIA $1.42
- Analyst Decision
- OTRK Strong Buy
- KZIA Strong Buy
- Analyst Count
- OTRK 1
- KZIA 1
- Target Price
- OTRK $45.00
- KZIA $20.00
- AVG Volume (30 Days)
- OTRK 68.7K
- KZIA 116.4K
- Earning Date
- OTRK 11-13-2024
- KZIA 11-15-2024
- Dividend Yield
- OTRK N/A
- KZIA N/A
- EPS Growth
- OTRK N/A
- KZIA N/A
- EPS
- OTRK N/A
- KZIA N/A
- Revenue
- OTRK $11,239,000.00
- KZIA $1,655,324.00
- Revenue This Year
- OTRK N/A
- KZIA $806.89
- Revenue Next Year
- OTRK $48.09
- KZIA N/A
- P/E Ratio
- OTRK N/A
- KZIA N/A
- Revenue Growth
- OTRK N/A
- KZIA 248000.00
- 52 Week Low
- OTRK $1.41
- KZIA $1.39
- 52 Week High
- OTRK $16.05
- KZIA $15.80
- Technical
- Relative Strength Index (RSI)
- OTRK 51.18
- KZIA 20.74
- Support Level
- OTRK $1.69
- KZIA $1.42
- Resistance Level
- OTRK $1.86
- KZIA $1.89
- Average True Range (ATR)
- OTRK 0.16
- KZIA 0.24
- MACD
- OTRK 0.01
- KZIA 0.02
- Stochastic Oscillator
- OTRK 47.54
- KZIA 1.40
About OTRK Ontrak Inc.
Ontrak Inc is an artificial intelligence (AI)-powered and technology-enabled behavioral healthcare company, whose mission is to help improve the health and save the lives of as many people as possible. The Company's technology-enabled platform utilizes claim-based analytics and predictive modeling to provide analytic insights throughout the delivery of our personalized care program. The company's integrated, technology-enabled OntrakTM solutions, a component of the PRE platform, are designed to treat members with behavioral conditions that cause chronic medical conditions such as diabetes, hypertension, coronary artery disease, COPD, and congestive heart failure.
About KZIA Kazia Therapeutics Limited
Kazia Therapeutics Ltd is an oncology-focused biotechnology company, developing anti-cancer drugs. The group is developing paxalisib, a potential treatment for glioblastoma; Cantrixil, being developed for the treatment of ovarian cancer; and Others. The company is also developing EVT801 for the treatment of various tumors. Maximum of revenue is earned from South Korea.